CDK4/6 blockade in breast cancer: current experience and future perspectives

References

• Global Burden of Disease Cancer Collaboration; Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017 Apr 1;3(4):524–548.
   PubMed Web of Science ®Google Scholar
• Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016 Jul;66(4):271–289.
   PubMed Web of Science ®Google Scholar
• Zardavas D, Tryfonidis K, Goulioti T, et al. Targeted adjuvant therapy in breast cancer. Expert Rev Anticancer Ther. 2016 Dec;16(12):1263–1275.
   PubMed Web of Science ®Google Scholar
• Lim YJ, Lee S-W, Choi N, et al. Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice. Breast Cancer Res Treat. 2017 Jun;163(3):555–563.
   PubMed Web of Science ®Google Scholar
• Zardavas D, Irrthum A, Swanton C, et al. Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol. 2015 Jul;12(7):381–394.
   PubMed Web of Science ®Google Scholar
• Zardavas D, Baselga J, Piccart M. Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol. 2013 Apr;10(4):191–210.
   PubMed Web of Science ®Google Scholar
• Zardavas D, Piccart-Gebhart M. Clinical trials of precision medicine through molecular profiling: focus on breast cancer. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Meet. 2015;35:e183–e190.
   Google Scholar
• Zardavas D, Piccart-Gebhart M. New generation of breast cancer clinical trials implementing molecular profiling. Cancer Biol Med. 2016 Jun;13(2):226–235.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57–70.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Duronio RJ, Xiong Y. Signaling pathways that control cell proliferation. Cold Spring Harb Perspect Biol. 2013 Mar 1;5(3):a008904.
   PubMed Web of Science ®Google Scholar
• Harashima H, Dissmeyer N, Schnittger A. Cell cycle control across the eukaryotic kingdom. Trends Cell Biol. 2013 Jul;23(7):345–356.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009 Mar;9(3):153–166.
   PubMed Web of Science ®Google Scholar
• Musgrove EA. Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors Chur Switz. 2006 Mar;24(1):13–19.
   PubMed Web of Science ®Google Scholar
• Satyanarayana A, Kaldis P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene. 2009 Aug 20;28(33):2925–2939.
   PubMed Web of Science ®Google Scholar
• Bertoli C, Skotheim JM, De Bruin RAM. Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol. 2013 Aug;14(8):518–528.
   PubMed Web of Science ®Google Scholar
• Harper JW, Adams PD. Cyclin-dependent kinases. Chem Rev. 2001 Aug;101(8):2511–2526.
   PubMed Web of Science ®Google Scholar
• Coudreuse D, Nurse P. Driving the cell cycle with a minimal CDK control network. Nature. 2010 Dec 23;468(7327):1074–1079.
   PubMed Web of Science ®Google Scholar
• Skotheim JM, Di Talia S, Siggia ED, et al. Positive feedback of G1 cyclins ensures coherent cell cycle entry. Nature. 2008 Jul 17;454(7202):291–296.
   PubMed Web of Science ®Google Scholar
• Zhang L, Fried FB, Guo H, et al. Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation. Blood. 2008 Feb 1;111(3):1193–1200.
   PubMed Web of Science ®Google Scholar
• Aggarwal P, Vaites LP, Kim JK, et al. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell. 2010 Oct 19;18(4):329–340.
   PubMed Web of Science ®Google Scholar
• Lamb J, Ramaswamy S, Ford HL, et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell. 2003 Aug 8;114(3):323–334.
   PubMed Web of Science ®Google Scholar
• Bienvenu F, Jirawatnotai S, Elias JE, et al. Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen. Nature. 2010 Jan 21;463(7279):374–378.
   PubMed Web of Science ®Google Scholar
• Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell. 2006 Oct 20;127(2):265–275.
   PubMed Web of Science ®Google Scholar
• Michalides R, Hageman P, Van Tinteren H, et al. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer. 1996 Mar;73(6):728–734.
   PubMed Web of Science ®Google Scholar
• Lundgren K, Holm K, Nordenskjld B, et al. Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer. Breast Cancer Res [Internet]. 2008 Oct [cited 2017 Jun 10];10(5). Available from: http://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2150
   PubMed Web of Science ®Google Scholar
• Koboldt DC, Fulton RS, McLellan MD, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012 Sep 23;490(7418):61–70.
   PubMed Web of Science ®Google Scholar
• Fumagalli D, Wilson TR, Salgado R, et al. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. Ann Oncol Off J Eur Soc Med Oncol. 2016 Oct;27(10):1860–1866.
   PubMed Web of Science ®Google Scholar
• Herschkowitz JI, He X, Fan C, et al. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res BCR. 2008;10(5):R75.
   PubMed Web of Science ®Google Scholar
• Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006 Apr 10;24(11):1770–1783.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Deng T, Jones R, et al. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest. 2010 Sep;120(9):3296–3309.
   PubMed Web of Science ®Google Scholar
• Arima Y, Hayashi N, Hayashi H, et al. Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer. Int J Cancer. 2012 Jun 1;130(11):2568–2579.
   PubMed Web of Science ®Google Scholar
• Monga M, Sausville EA. Developmental therapeutics program at the NCI: molecular target and drug discovery process. Leukemia. 2002 Apr;16(4):520–526.
   PubMed Web of Science ®Google Scholar
• Fornier MN, Rathkopf D, Shah M, et al. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res. 2007 Oct 1;13(19):5841–5846.
   PubMed Web of Science ®Google Scholar
• Tan AR, Yang X, Berman A, et al. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res. 2004 Aug 1;10(15):5038–5047.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Gabrilove J, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from cancer and leukemia group B study 19805. Clin Cancer Res. 2005 Jun 1;11(11):4176–4181.
   PubMed Web of Science ®Google Scholar
• Luke JJ, D’Adamo DR, Dickson MA, et al. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clin Cancer Res. 2012 May 1;18(9):2638–2647.
   PubMed Web of Science ®Google Scholar
• Khalil HS, Mitev V, Vlaykova T, et al. Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance. J Biotechnol. 2015 May 20;202:40–49.
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Faivre S, Laurence V, et al. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer 1990. 2010 Dec;46(18):3243–3250.
   Google Scholar
• Benson C, White J, De Bono J, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer. 2007 Jan 15;96(1):29–37.
   PubMed Web of Science ®Google Scholar
• Schwartz GK, LoRusso PM, Dickson MA, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (schedule 2/1). Br J Cancer. 2011 Jun 7;104(12):1862–1868.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012 Jan 15;18(2):568–576.
   PubMed Web of Science ®Google Scholar
• DeMichele A, Clark AS, Tan KS, et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res. 2015 Mar 1;21(5):995–1001.
   PubMed Web of Science ®Google Scholar
• Tryfonidis K, Zardavas D, Katzenellenbogen BS, et al. Endocrine treatment in breast cancer: cure, resistance and beyond. Cancer Treat Rev. 2016;50:68–81.
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16(1):25–35.
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016 Nov 17;375(20):1925–1936.
   PubMed Web of Science ®Google Scholar
• Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor–positive advanced breast cancer. N Engl J Med. 2015 Jul 16;373(3):209–219.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016 Apr;17(4):425–439.
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown J, Lang I, et al. Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18). J Clin Oncol. 2017;35(suppl; abstr 1001). Presented at the ASCO Annual Meeting 2017.
   Google Scholar
• Gelbert LM, Cai S, Lin X, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014 Oct;32(5):825–837.
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Tamura K, Kondo S, et al. Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer. Cancer Chemother Pharmacol. 2016 Aug;78(2):281–288.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Rosen LS, Tolaney SM, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 2016 Jul 1;6(7):740–753.
   PubMed Web of Science ®Google Scholar
• Dickler M, Tolaney S, Rugo H, et al. MONARCH1: results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2− breast cancer, after chemotherapy for advanced disease. J Clin Oncol. 2016;34(suppl; abstr 510). 2016 ASCO Annual Meeting.
   Google Scholar
• Sledge GW, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2? Advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017 Jun 3;JCO.2017.73.758.
   Web of Science ®Google Scholar
• Raub TJ, Wishart GN, Kulanthaivel P, et al. Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft. Drug Metab Dispos. 2015 Jul 27;43(9):1360–1371.
   PubMed Web of Science ®Google Scholar
• Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors. Clin Cancer Res. 2017 Jul 1;23(13):3251–3262.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for hr-positive, advanced breast cancer. N Engl J Med. 2016 Nov 3;375(18):1738–1748.
   PubMed Web of Science ®Google Scholar
• Chow LW, Lam C-K, Loo WT. Abstract P6-11-04: OOTR-N007: a phase II neoadjuvant study of letrozole plus palbociclib in postmenopausal patients with ER positive, HER2 negative breast cancer. Cancer Res. 2015 May 1;75(9 Supplement):P6-11-04-P6-11-04.
   PubMed Web of Science ®Google Scholar
• Ma CX, Gao F, Luo J, et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin Cancer Res. 2017 Mar 7;23:4055–4065.
   PubMed Web of Science ®Google Scholar
• Corona SP, Ravelli A, Cretella D, et al. CDK4/6 inhibitors in HER2-positive breast cancer. Crit Rev Oncol Hematol. 2017;112:208–214.
   PubMed Web of Science ®Google Scholar
• Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001 Jun 28;411(6841):1017–1021.
   PubMed Web of Science ®Google Scholar
• Yu Q, Sicinska E, Geng Y, et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell. 2006 Jan;9(1):23–32.
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Conklin D. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res [Internet]. 2009 Oct [cited 2017 Jun 11];11(5). Available from: http://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2419
   PubMed Web of Science ®Google Scholar
• Goel S, Wang Q, Watt AC, et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell. 2016 Mar 14;29(3):255–269.
   PubMed Web of Science ®Google Scholar
• Clark A, Wang X, Troxel A, et al. Abstract P4-22-14: single agent palbociclib with or without trastuzumab for the treatment of Rb+ advanced breast cancer. Cancer Res. 2017 Feb 15;77(4 Supplement):P4-22-14-P4-22–14.
   PubMed Web of Science ®Google Scholar
• Gianni L, Bisagni G, Colleoni M, et al. Abstract P4-21-39: neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: effect on Ki67 during and after treatment. A phase II Michelangelo study. Cancer Res. 2017 Feb 15;77(4 Supplement):P4-21-39-P4-21–39.
   PubMed Web of Science ®Google Scholar
• McClendon AK, Dean JL, Rivadeneira DB, et al. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle Georget Tex. 2012 Jul 15;11(14):2747–2755.
   PubMed Web of Science ®Google Scholar
• Asghar U, Barr AR, Cutts R, et al. Single-cell dynamics determines response to CDK4/6 inhibition in triple negative breast cancer. Clin Cancer Res. 2017 Jun 12;23:5561–5572.
   PubMed Web of Science ®Google Scholar
• Garrido-Castro AC, Goel S. CDK4/6 inhibition in breast cancer: mechanisms of response and treatment failure. Curr Breast Cancer Rep. 2017 Mar;9(1):26–33.
   PubMed Web of Science ®Google Scholar
• Finn R, Jiang Y, Rugo H, et al. Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER +/HER2– advanced breast cancer (ABC). Ann Oncol [Internet]. 2016 Oct 1 [cited 2017 Jun 26];27(suppl_6). Available from: https://academic.oup.com/annonc/article/2800514/Biomarker
   Google Scholar
• Raspé E, Coulonval K, Pita JM, et al. CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib. EMBO Mol Med. 2017 May 31;9:1052–1066.
   PubMed Web of Science ®Google Scholar
• Wang H, Nicolay BN, Chick JM, et al. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. Nature. 2017 Jun 15;546(7658):426–430.
   PubMed Web of Science ®Google Scholar
• Dean JL, Thangavel C, McClendon AK, et al. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene. 2010 Jul 15;29(28):4018–4032.
   PubMed Web of Science ®Google Scholar
• Dean JL, McClendon AK, Hickey TE, et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle. 2012 Jan 15;11(14):2756–2761.
   PubMed Web of Science ®Google Scholar
• Malorni L, Piazza S, Ciani Y, et al. A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. Oncotarget. 2016 13;7(42):68012–68022.
   PubMed Web of Science ®Google Scholar
• Zardavas D, Maetens M, Irrthum A, et al. The AURORA initiative for metastatic breast cancer. Br J Cancer. 2014 Nov 11;111(10):1881–1887.
   PubMed Web of Science ®Google Scholar
• O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016 Jul;13(7):417–430.
   PubMed Web of Science ®Google Scholar
• Herrera-Abreu MT, Palafox M, Asghar U, et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. 2016 15;76(8):2301–2313.
   PubMed Web of Science ®Google Scholar
• Yang C, Li Z, Bhatt T, et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene. 2017 Apr 20;36(16):2255–2264.
   PubMed Web of Science ®Google Scholar
• Maurer C, Martel S, Zardavas D, et al. New agents for endocrine resistance in breast cancer. Breast Edinb Scotl. 2017;34:1–11.
   PubMed Web of Science ®Google Scholar